The Food and Drug Administration approved a pill version of the weight-loss injectable drug Wegovy. The focus on cash-paying consumers aims to revive Novo’s slowing sales growth and turbocharge the next stage of expansion for the ⁠wider market. Lilly is awaiting US approval for its weight-loss pill, which could come as early as March. Novo does not expect the pill to cannibalise its injectable Wegovy business. Analysts and ‌industry executives also do not expect oral GLP-1s to fully replace injections, but say pills could capture 20 per cent of the global obesity drug market by 2030.

Source: The Irish Times December 23, 2025 16:32 UTC